CardiacAssist raises funds for European launch:
This article was originally published in Clinica
Executive Summary
CardiacAssist has secured $33 million in a financing led by Advent Venture Partners. The Pittsburgh, Pennsylvania company plans to use the funds to support sales and marketing of its ventricular assist devices (VAD) in Europe, as well as for US clinical trials. The company has developed its implantable VAD into a larger, external pump system. This will allow it to address the much larger cardiogenic shock market, which is estimated at some $1 billion.